Endocrine Switch Plus Ribociclib Active in Post-CDK4/6 Inhibitor Progression

(MedPage Today) -- CHICAGO--Progression-free survival (PFS) in advanced hormone receptor (HR)-positive/HER2-negative breast cancer improved significantly in patients who received ribociclib (Kisqali) and a different endocrine therapy after...